We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Clinical Trial Information Line
1-877-ALNYLAM
clinicaltrials@alnylam.com
Clinical Trial Information Line
1-877-256-9526
clinicaltrials@alnylam.com
Alzheimer's Disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The purpose of this study is to:
* Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)
* Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
This is in the inclusion criteria above
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Clinical Trial Information Line
1-877-ALNYLAM
clinicaltrials@alnylam.com
Clinical Trial Information Line
1-877-256-9526
clinicaltrials@alnylam.com
The study is sponsored by Alnylam Pharmaceuticals and is in collaboration with Regeneron Pharmaceuticals.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
